• Explore /
  • Poster
  • / Nivolumab in advanced hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis: Safety and clinical outcomes in a retrospective case series.

Nivolumab in advanced hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis: Safety and clinical outcomes in a retrospective case series.

Abstract Poster

Authors

null

Swetha Kambhampati

University of California San Francisco, San Francisco, CA

Swetha Kambhampati , Kelly Bauer , Jimmy Hwang , Andrea Grace Bocobo , John Dozier Gordan , Robin Kate Kelley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 496)

DOI

10.1200/JCO.2018.36.4_suppl.496

Abstract #

496

Poster Bd #

N20

Abstract Disclosures

Similar Posters

First Author: William Joseph Chapin

Poster

2017 Gastrointestinal Cancers Symposium

Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.

Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.

First Author: Ignacio Melero

First Author: Timothy J. Brown

First Author: Thomas Yau